scholarly journals Is the postoperative discomfort after connective tissue harvesting from the palate influenced by the use of a bipolar coagulator? A randomized controlled trial

2021 ◽  
Author(s):  
Federico Tirone ◽  
Stefano Salzano ◽  
Paola Panuello ◽  
Laura Pozzatti ◽  
Donata Rodi
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Postoperative Discomfort

A comparison of the effects of exercises plus connective tissue massage to exercises alone in women with fibromyalgia syndrome: a randomized controlled trial

2017 ◽  
Vol 37 (11) ◽  
pp. 1799-1806 ◽  
Author(s):  
Seyda Toprak Celenay ◽  
Bahar Anaforoglu Kulunkoglu ◽  
Mustafa Ertugrul Yasa ◽  
Cansu Sahbaz Pirincci ◽  
Necmiye Un Yildirim ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Fibromyalgia Syndrome ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Connective Tissue Massage

Use of platelet gel with connective tissue grafts for root coverage: a randomized-controlled trial

2008 ◽  
Vol 35 (3) ◽  
pp. 255-262 ◽  
Author(s):  
Huseyin Gencay Keceli ◽  
Dilek Sengun ◽  
Atilla Berberoğlu ◽  
Erdem Karabulut
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Controlled Trial ◽  
Root Coverage ◽  
Platelet Gel ◽  
Randomized Controlled ◽  
Tissue Grafts

scholarly journals A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone on recurrent spontaneous abortion with undifferentiated connective tissue diseases: Protocol for the immunosuppressant regimens for Living FEtuses (ILIFE) Trial

2020 ◽  
Author(s):  
Shaoying Yang ◽  
Ruoning Ni ◽  
Yikang Lu ◽  
Suli Wang ◽  
Feng Xie ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Spontaneous Abortion ◽  
Pregnancy Outcomes ◽  
Low Dose ◽  
Controlled Trial ◽  
Recurrent Spontaneous Abortion ◽  
Open Label ◽  
Randomized Controlled ◽  
Dose Prednisone

Abstract Background: Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes, and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressant to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD.Methods: The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD.Discussion: This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease. Trial registration: ClinicalTrials.gov, NCT03671174. Registered on 14 September 2018. https://www.clinicaltrials.gov/ct2/show/NCT03671174

scholarly journals A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Shaoying Yang ◽  
Ruoning Ni ◽  
Yikang Lu ◽  
Suli Wang ◽  
Feng Xie ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Pregnancy Outcomes ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Controlled Trial ◽  
Open Label ◽  
Randomized Controlled ◽  
Adverse Pregnancy ◽  
Dose Prednisone

Abstract Background Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressants to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD. Methods The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD. Discussion This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease. Trial registration ClinicalTrials.gov NCT03671174. Registered on 14 September 2018.

Sign in / Sign up

Export Citation Format

Share Document